James Emmett Young Acquires 6,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young purchased 6,000 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were acquired at an average cost of $5.65 per share, for a total transaction of $33,900.00. Following the completion of the transaction, the chief financial officer now owns 30,000 shares of the company’s stock, valued at $169,500. This trade represents a 25.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

James Emmett Young also recently made the following trade(s):

• On Monday, January 27th, James Emmett Young bought 24,000 shares of TriSalus Life Sciences stock. The shares were acquired at an average price of $5.40 per share, for a total transaction of $129,600.00.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI opened at $5.57 on Friday. TriSalus Life Sciences, Inc. has a 52-week low of $3.50 and a 52-week high of $10.42. The company has a market capitalization of $169.83 million, a PE ratio of -2.24 and a beta of 0.51. The company has a fifty day moving average of $4.68 and a 200-day moving average of $4.75.

Wall Street Analyst Weigh In

A number of research firms have commented on TLSI. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Cantor Fitzgerald assumed coverage on shares of TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 target price on the stock. Canaccord Genuity Group reduced their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Finally, Northland Securities started coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They set an “outperform” rating and a $12.50 price objective for the company. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $11.79.

Hedge Funds Weigh In On TriSalus Life Sciences

Several large investors have recently bought and sold shares of the company. Walleye Capital LLC acquired a new position in shares of TriSalus Life Sciences in the third quarter valued at approximately $66,000. Virtu Financial LLC acquired a new position in TriSalus Life Sciences in the 3rd quarter valued at approximately $92,000. Vestcor Inc bought a new position in shares of TriSalus Life Sciences during the third quarter valued at $108,000. MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences during the third quarter worth $184,000. Finally, Geode Capital Management LLC grew its stake in shares of TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after purchasing an additional 62,542 shares during the last quarter. 2.58% of the stock is currently owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.